Danlox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Danlox

Property Description
Active ingredient Omeprazole (a substituted benzimidazole)
Form Gastro-resistant capsules, tablets, or solution for injection
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Managing excessive stomach acid and acid reflux
Origin Synthetic compound (Prodrug)

What is Danlox and What Type of Medicine is It?

Danlox is a prescription-only medicine used to reduce the amount of acid produced by the stomach. It is officially classified as a Proton Pump Inhibitor (PPI), which is a type of antisecretory agent. Its use in managing acid-related disorders is a documented property of the drug's pharmacological profile.

Omeprazole is used for treating symptoms related to acid flowing back into the esophagus. This medicine helps alleviate discomfort by providing sustained control over stomach acid levels.


Composition, Origin, and Available Forms

The active substance in Danlox is Omeprazole, a synthetic compound derived from the substituted benzimidazole chemical group. Omeprazole functions as a prodrug, meaning it remains inert until it is transformed by the acidic environment of the stomach lining to exert its therapeutic action. This reliance mandates its formulation as a gastro-resistant product. The drug is most commonly available for oral intake as hard capsules or tablets, but it is also prepared as a powder for solution for injection or infusion for intravenous administration when oral use is not feasible. Omeprazole belongs to the class of medicines used for acid-related disorders.


How Does Omeprazole Deliver its Effect?

Omeprazole delivers its therapeutic effect by creating an irreversible inhibition of the H^+/K^+-ATPase enzyme system, commonly referred to as the proton pump, which is the final stage in gastric acid production. By disabling the majority of these pumps, Danlox ensures a reduction in both basal and stimulated acid secretion. This mechanism achieves the general therapeutic purpose of Danlox: providing sustained relief and a low-acid environment that supports the natural healing of the esophagus and stomach lining.

Regulatory References

  1. NIH/NLM: Omeprazole

What side effects are possible with Danlox?

Possible Side Effects and Safety Information

The safety profile of Danlox (Omeprazole) is established through official regulatory documentation, classifying adverse reactions by frequency and the body system affected.


Official Classification of Adverse Reactions

The most common reactions (reported in 1% to 10% of patients) primarily involve the Gastrointestinal and Nervous Systems. These commonly reported effects include headache, abdominal pain, constipation, diarrhea, flatulence, nausea, and vomiting.

Uncommon reactions (reported in 0.1% to <1% of patients) can affect other domains, such as insomnia, dizziness, skin rash, and elevations in liver enzyme levels.

Rare adverse reactions (reported in 0.01% to <0.1% of patients) involve more serious conditions, including severe hypersensitivity reactions (such as angioedema and anaphylactic shock) and severe skin reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Rare effects also involve blood and lymphatic system disorders (e.g., leukopenia, thrombocytopenia) and acute interstitial nephritis.


Contextual Safety Patterns

Regulatory documents note specific safety considerations linked to the duration of therapy. Prolonged use, typically one year or longer, is associated with a potential increase in risk for osteoporosis-related fractures (hip, wrist, spine) and hypomagnesaemia (low serum magnesium). Furthermore, use is constrained by pre-existing conditions, such as severe hepatic impairment, where clearance may be reduced, and by documented safety issues arising from co-administration with certain antiretroviral medicines.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the active ingredient Omeprazole (Danlox) is generally associated with manifestations that are officially documented as transient and not serious in nature, even following the ingestion of substantial doses.

Documented Overdose Manifestations

Regulatory labeling documents the clinical presentation of overexposure primarily involves the gastrointestinal and central nervous systems. Documented symptoms include nausea, vomiting, abdominal pain, and diarrhea. Central nervous system effects such as headache, dizziness, lethargy (somnolence), and temporary confusion may also occur. Less common manifestations reported in regulatory summaries include blurred vision, increased sweating, and tachycardia.

Required Emergency Actions

The official government guidance mandates that any patient with a suspected overdose seek immediate medical attention. This urgent action is required regardless of the initial perceived severity of symptoms. Furthermore, the prescribing information recommends immediately contacting a certified poison control center or emergency services. Management of an Omeprazole overdose is entirely symptomatic and supportive treatment, as dictated by regulatory authorities. No specific antidote is known to reverse the drug’s effects. Due to the high protein-binding nature of the active ingredient, standard procedures like hemodialysis are not expected to be an effective measure for removal. Continuous monitoring of the patient’s condition is required in a professional setting.

Therapeutic Uses of Danlox

What Danlox Treats: Main Uses and Benefits

Danlox is relevant for use in therapeutic domains involving conditions characterized by periods of heightened symptoms, particularly those presenting with systemic or localized discomfort. This medicine is commonly used to help with two main condition categories: endometriosis and hereditary angioedema.


In clinical settings that involve acute or unstable symptom patterns, Danlox may assist with managing symptoms related to physical discomfort and symptoms that interfere with daily functioning. For patients with conditions involving inflammatory or irritative processes like endometriosis, the therapy helps ease the overall symptom burden. For recurrent or episodic manifestations such as hereditary angioedema, it supports the patient during difficult episodes. The therapy may assist with maintaining functional stability during symptomatic periods.

Quick Fact Block

Quick Fact: Contributes to easing the overall symptom load

“The medicine supports general well-being during symptomatic phases.”

Regulatory References

  1. NIH NCBI Bookshelf overview on Danazol

Eligibility and Restrictions for Use

Danlox (Omeprazole) is governed by specific regulatory rules detailing the populations that can or cannot use the medicine. These rules are defined by official governmental health authorities.

Contraindicated Populations

Classification Rule
Absolute Prohibition Patients with known hypersensitivity to Omeprazole, substituted benzimidazoles (e.g., other PPIs), or any component of the formulation.
Coadministration Patients concurrently receiving Nelfinavir or Rilpivirine (antivirals) must not use Danlox.

Age and Reproductive Status

  • Adults and Elderly: Use is permitted. Dose adjustment for the elderly is generally not needed.
  • Pediatric Use: Established for children 1 year of age and older for specific indications; safety and efficacy are not established for infants younger than 1 year.
  • Pregnancy and Lactation: Use is permitted. Based on epidemiological studies, Omeprazole is not likely to influence the child during pregnancy or while breastfeeding at therapeutic doses.

Eligibility-Related Restrictions

  • Hepatic Impairment: Use requires caution due to impaired drug metabolism; a lower maintenance dose may be required.
  • Clopidogrel Therapy: Concomitant use with Clopidogrel is discouraged as a precautionary measure due to potential effects on anti-platelet activity.
  • Alarm Symptoms: If symptoms like unintentional weight loss, recurrent vomiting, or melena are present, Danlox must be used only after gastric malignancy has been excluded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Danlox (Omeprazole) is structured primarily by its effect on gastric pH and its ability to inhibit specific liver enzymes. Regulatory documents define several interaction-related constraints.

Contraindicated and Avoided Combinations

The co-administration of Danlox with the antiretroviral medicines Nelfinavir and Rilpivirine is formally contraindicated in official labeling due to the risk of significantly reducing the plasma concentration of the antiretrovirals. Additionally, the co-administration of Atazanavir or the herbal product St. John's Wort is strongly advised against, as the latter can reduce omeprazole exposure.

Pharmacokinetic Effects

Danlox is a documented inhibitor of the metabolic enzymes CYP2C19 and CYP3A4. This inhibition may increase the systemic exposure (plasma levels) of co-administered medicines, including Digoxin, Tacrolimus, and Cilostazol. Conversely, the reduction of intragastric acidity limits the absorption of products that require an acidic environment, such as certain antifungals (e.g., Ketoconazole) and iron salts.

Interaction-Related Restrictions

The official label states that co-administration with Clopidogrel may result in diminished anti-platelet activity. Furthermore, the drug is noted to interfere with the diagnostic assessment of Chromogranin A (CgA) levels, requiring that Danlox be temporarily stopped at least 14 days prior to the test.

Mechanism of Action

Omeprazole functions as a Proton Pump Inhibitor (PPI), exerting its action through interaction with the final molecular structure responsible for acid production. The mechanism is defined by three core domains: acid-activated transformation, irreversible enzyme inhibition, and dependence on cellular renewal.

Irreversible Blockade of the H^+/ K^+-ATPase Enzyme

Omeprazole is a prodrug that is activated by the extreme pH within the stomach's acid-secreting cells, converting it into an active inhibitor. This active form then forms a covalent, permanent bond with the H^+/ K^+-ATPase enzyme (the proton pump), the machinery responsible for pumping hydrogen ions ( H^+) into the stomach.

Physiological Consequence: Sustained Reduction in Acid Output

Irreversible deactivation of the proton pump interrupts the final common pathway of acid production, making the blockade independent of upstream hormonal or neural signals. The physiological effect—a significant and sustained reduction in gastric acidity—persists beyond the drug's presence in the bloodstream because acid production only resumes when the stomach lining synthesizes and incorporates new enzyme molecules.

Systemic Effect on Gastric pH

This H^+ suppression leads to a significant and prolonged increase in gastric pH (lowered acidity). This elevated pH also causes the deactivation of the enzyme pepsin, which requires a highly acidic environment to maintain its active state.

Dosage and Administration Information

Official Administration Guidelines

Danlox (Omeprazole) is primarily administered via the oral route using delayed-release capsules, tablets, or oral suspension. Intravenous (IV) administration is reserved exclusively as a temporary substitution when the oral route is not feasible, such as in certain hospital settings.

The proper administration of oral forms is critical to maintain the integrity of the gastro-resistant coating. Therefore, capsules and tablets must be swallowed whole and must not be crushed or chewed. If difficulty swallowing is present, the capsule's contents (pellets) may be mixed with a small amount of water or soft food, but the pellets must still be swallowed immediately without chewing.

The medicine is typically taken once daily and must be scheduled before a meal, preferably in the morning, to align with the body’s acid production cycle. Standard dosing regimens for adults are commonly 20 mg or 40 mg once daily. However, doses for pathological hypersecretory conditions may be higher, sometimes up to 360 mg per day, which requires the total daily dose to be divided and taken more than once. Treatment duration usually ranges from four to eight weeks for acute use, with maintenance use extending up to twelve months for certain conditions.

Official labels specify required modifications for specific populations. A dose adjustment is necessary for patients with severe hepatic impairment, where a maximum dose of 20 mg daily is typically established. Conversely, dose adjustments are generally not required for older adults or those with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Danlox


Evidence for Use in Managing Acid Reflux and GERD

Research on Danlox (Omeprazole) for managing Gastroesophageal Reflux Disease (GERD) symptoms, such as heartburn and regurgitation, has been extensive. This area has been a focus of many short-term and intermediate-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and applied in studies examining patient-reported experiences. The findings describe patterns observed in the studies regarding the monitored frequency and intensity of reflux-related discomfort.

What remains uncertain involves the long-term management of reflux. While the initial trials provide insight into short-term changes, research is ongoing regarding the clinical necessity for continuous, long-term use in all patients whose symptoms were stable during observation. Findings related to certain patient subgroups, particularly those without visible damage in the esophagus, were mixed across studies.


Evidence for Healing and Preventing Esophageal Damage

The role of Danlox in addressing physical damage to the esophagus, known as erosive esophagitis, was evaluated in controlled clinical trials. These studies primarily focused on two things: achieving mucosal healing (the documented change in the irritated lining) and examining the recurrence of the damage. The primary measurement was the rate of endoscopic confirmation of mucosal status over defined time intervals.

Research also examined long-term maintenance outcomes related to conditions involving inflammatory or irritative states. Studies monitored patient groups for up to one year to see how often the lesions returned. Studies reported on the patterns observed regarding mucosal healing across numerous trials of similar design.


Evidence for Treating and Preventing Peptic Ulcers

Danlox was studied for the resolution of gastric and duodenal ulcers. The research utilized RCTs to assess two main scenarios: addressing active ulcers and exploring their prevention, especially in patients at high risk due to taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or those undergoing treatment for H. pylori infection. The studies monitored measurements related to physical repair and to outcomes linked to inflammatory or irritative states.

Findings describe patterns observed in the studies regarding the monitored rates of ulcer resolution within the defined treatment intervals. For prevention, research highlights changes measured during the study period concerning how many at-risk patients developed new ulcers compared to control groups. Danlox was observed in combination studies with antibiotics, where research explored its use alongside therapy for H. pylori bacteria.

Key Studies & References

  1. standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials
  2. Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition
  3. Omeprazole - StatPearls - NCBI Bookshelf (Comprehensive Drug Monograph)
  4. Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea
  5. Assessing Safety Concerns in Omeprazole Use: An Observational Study of Potentially Inappropriate Prescriptions and Patient Adherence
  6. New study examines long-term effects of common heartburn medications on kidney and cardiovascular health | Karolinska Institutet (Observational study context)

Frequently Asked Questions (FAQ)

Common questions about Danlox (FAQ)


Q: How quickly should I expect to feel the effects of Danlox?

A: According to official product information, the acid-reducing action, known as the antisecretory effect, generally begins within one hour of taking the medicine. The full acid-inhibiting effect typically increases with repeated daily dosing, with maximal effect often observed after approximately four days of treatment.


Q: Is it better to take Danlox in the morning or at night?

A: Official administration guidelines usually suggest taking this medicine once daily before a meal. Studies indicate that scheduling the dose in the morning may provide optimal, consistent control of stomach acidity throughout a 24-hour period.


Q: What is the longest period of time people typically take Danlox for?

A: The appropriate duration of use varies widely based on the specific condition being addressed. While acute use for healing may last 4 to 8 weeks, official documents note that long-term maintenance therapy for specific conditions, such as preventing the recurrence of esophageal damage, can be required and may extend up to 12 months or longer under clinical review.


Q: Will Danlox make me feel tired or drowsy?

A: Official reports on side effects list dizziness as a common reaction and fatigue as a documented adverse reaction. While the term 'drowsiness' itself is not explicitly listed, patients who experience these effects should exercise caution, particularly when driving or operating machinery.


Q: Is Danlox generally safe for older adults?

A: Official information states that dose adjustments are generally not required for older adults with normal kidney and liver function. However, older patients using the medicine long-term are advised to discuss the documented risk factors, such as bone fracture and nutrient deficiency, with a healthcare provider.


Q: Has Danlox been studied in children or adolescents?

A: Yes, regulatory documents confirm that use is established and studied in pediatric patients aged 1 year and older for certain indications like treating acid reflux. Safety and effectiveness have not been established for infants younger than 1 year.


Q: Do alcohol and Danlox have any known interactions?

A: There is no known interaction that chemically affects how the medicine works in the body. However, since alcohol can stimulate stomach acid production, consuming alcohol may counteract the medicine's effect of reducing acidity.


Q: Are there different strengths or dosages of Danlox, and why?

A: Yes, common strengths are 20 mg and 40 mg. Official regulatory information confirms that different strengths are available to match the severity of the condition or the specific treatment phase. For instance, a higher dose may be used for healing severe damage, while a lower dose is often used for long-term symptom control.


Q: Why do some people need to take Danlox for a long time?

A: Long-term use is typically necessary for maintenance therapy to prevent the recurrence of severe conditions, such as healed esophageal damage. Regulatory documents warn that continuous use, usually for one year or longer, is associated with the potential for side effects, including bone fracture and low magnesium levels (hypomagnesemia).


Q: Is Danlox addictive or habit-forming?

A: No, official regulatory classifications do not list this medicine as a controlled substance. It is not considered to be addictive or habit-forming.


Q: Is it normal to feel a bit restless when first starting treatment with Danlox?

A: Insomnia (difficulty sleeping) is listed in official documents as an uncommon side effect, meaning it occurs in a small percentage of patients. This type of central nervous system effect may be related to feelings of restlessness when initiating treatment.


Q: Why do some people say they have trouble sleeping on Danlox?

A: Insomnia (difficulty sleeping) is a specifically recognized uncommon adverse reaction that has been reported in clinical trials and post-marketing surveillance.


Q: Can I crush or chew Danlox tablets if I have trouble swallowing pills?

A: No, the delayed-release tablets or capsules must be swallowed whole and must not be crushed or chewed. This strict instruction is necessary to protect the special gastro-resistant coating. If swallowing whole pills is difficult, the contents (pellets) of the capsule may be mixed with certain soft foods, but the pellets themselves must still be swallowed whole.


Q: How long after stopping Danlox will it be completely out of my system?

A: While the drug substance is quickly cleared from the bloodstream, its profound acid-inhibiting effect lasts much longer. When the medicine is stopped, normal acid-secreting activity returns gradually over approximately 3 to 5 days, as the body synthesizes new acid-producing enzymes.


Q: If I miss a dose of Danlox, what is the generally recommended next step?

A: Patient instructions from regulatory sources generally state that if a dose is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose. If so, patients are generally advised to skip the missed dose and resume their regular schedule. Patients are advised to not take two doses to make up for the missed one.


Q: Can I take pain relievers like Tylenol or Advil while on Danlox?

A: Official labels detail interactions with specific prescription drugs, but not all common over-the-counter pain relievers. Patients should confirm the suitability of all over-the-counter pain relievers, including those in the NSAID class (like ibuprofen), with their healthcare provider.


Q: Are there any vitamins or supplements that should NOT be taken with Danlox?

A: Official warnings specifically advise against co-administering the herbal product St. John’s Wort, as it may reduce the medicine’s effectiveness. Furthermore, regulatory documents highlight that long-term use (one year or more) is associated with potential risks of Vitamin B12 deficiency and low magnesium (hypomagnesemia).

How should Danlox be stored and disposed of?

Official Storage Conditions for Danlox

Danlox (Omeprazole) must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), with a mandatory requirement to protect from moisture and light. The medicine must remain in its original container or packaging, and if provided in a bottle, the cap must be kept tightly closed to maintain product stability.

Condition Type Requirement
Temperature Range Controlled Room Temperature (Max 30 C)
Environmental Protection Protect from moisture and light
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Any unused or expired Danlox must be disposed of in accordance with local regulations for pharmaceutical waste. Regulatory guidance explicitly states that the medicine must not be flushed down the toilet or poured into a drain unless specific local guidelines permit this action. Patients are instructed to utilize drug take-back programs or follow official household disposal procedures if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Danlox found in:

A-Z Index: